FF EAI Robotics (FFR)

The supplied evidence does not describe FF EAI Robotics (FFR). The only source provided is a press release about Debiopharm's antibody-drug conjugate linker research, which contains no mention of FF EAI Robotics, FFR, robotics, or any related company, product, or platform. Because no official website, Wikipedia entry, registry record, or other brand-sense evidence was supplied, this entry cannot be written as a commercial brand dossier without inventing facts. The name suggests a possible robotics or embodied-AI venture, but that is an inference from the string itself, not evidence. This record is therefore flagged for review and kept deliberately short. If verified material becomes available — an official site, corporate registry filing, funding announcement, or product documentation — the dossier should be rebuilt around that evidence with proper taxonomy classification, ownership, headquarters, and history.

• 2026.10.14

  Reported2026.10.14

  FF EAI Robotics signs definitive agreement to acquire Faraday Future's robotics assets and business[2]FF EAI Robotics签署最终协议收购Faraday Future机器人资产及业务finance.sina.com.cn

  On October 14, 2026, FF EAI Robotics (FFR) announced it signed a definitive agreement with Faraday Future (NASDAQ: FFAI) under which FFR will acquire FFAI's robotics assets and business at a valuation of about $200 million, issuing shares to FFAI at $2.246 per share, roughly a 50% premium to the $1.50 close on the October 12 signing day. Under the agreement, FFAI's robotics business is valued at about $200 million and FFR at about $60 million; the parties expect to complete all closing by the end of the month, after which FFAI will hold about 65.7% of FFR.

• 2026.10.14

  Reported2026.10.14

  FF EAI Robotics signs first-round PIPE financing of up to $10 million[2]FF EAI Robotics签署最终协议收购Faraday Future机器人资产及业务finance.sina.com.cn

  Alongside the acquisition announcement on October 14, 2026, FF EAI Robotics (FFR) announced it completed the signing of a first-round PIPE financing of up to $10 million, priced at market with no price discount and no warrants. The round opened only about $10 million of funding capacity, and after closing PIPE investors will hold about 5.5% of FFR, subject to a six-month lock-up or until a resale registration goes effective.

Read more

1. 1Debiopharm's Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistancefinanznachrichten.de
2. 2FF EAI Robotics签署最终协议收购Faraday Future机器人资产及业务finance.sina.com.cn
3. 3贾跃亭FFR合并FF机器人，估值2亿美元融资1000万tech.ifeng.com